Rankings for Scientist

University, Subject, Country, Region, World

Federico Rojo Fundacion Jimenez Diaz
Federico Rojo

Federico Rojo
AD Scientific Index 2024

Fundacion Jimenez Diaz
Others
Fundacion Jimenez Diaz
Registration, Add Profile, Premium Membership print Print Your Certificate
Federico Rojo 		SCORES RANKINGS
In Fundacion Jimenez Diaz (32) In Spain (45,347) In Europe (494,156) World (1,615,803)
Total H Index 74 #4 #489 Top 3% #8,153 #23,973 Top 3%
Last 6 years H Index 51 #4 #403 Top 3% #6,523 #19,641 Top 3%
Last 6 years / Total H Index
 0.689
Total i10 Index 228 #5 #587 Top 3% #8,147 #23,282 Top 3%
Last 6 years i10 Index 175 #5 #412 Top 3% #6,070 #17,545 Top 3%
Last 6 years / Total i10 Index 0.768
Total Citation 29,774 #4 #362 Top 3% #6,806 #20,995 Top 3%
Last 6 years Citation 10,210 #6 #577 Top 3% #9,928 #29,949 Top 3%
Last 6 years / Total Citation 0.343
Others * Click for your subject rankings
cancer | biomarker | breast | oncology | 		- - - -
* May 30, 2024 According to Total H Index. BETA VERSION. Subject field ranking in world, region, country and university is beta version since subject field 'others' (160 scientists profile whose branch cannot be determined, not yet edited or determined) is excluded, so the ranking will change as the others fields are edited. Please note that.
 Top % 3: Indicates that the scientist is among the Top 3% Scientists in the specified subject among the scientists in the AD Scientific Index in the World and/or Country. 
Use [email protected] to report an inappropriate profile, death, or other conditions that would require the deletion of the relevant profile.  Data Privacy Policy:You can send a message to [email protected] to have your information removed from here, and your data will be deleted within 5 business days at the latest. Free of charge changes: University/institution changes (by emailing [email protected] with your AD Scientific Index ID number and evidence) Paid changes: Click for Changes, Registration, Adding Profile, Premium Membership 
person_outline Federico Rojo's MOST POPULAR ARTICLES
1-) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt KE O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, ... Cancer research 66 (3), 1500-1508, 2006 28972006
2-) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer A Carracedo, L Ma, J Teruya-Feldstein, F Rojo, L Salmena, A Alimonti, ... The Journal of clinical investigation 118 (9), 3065-3074, 2008 16102008
3-) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells MA Molina, J Codony-Servat, J Albanell, F Rojo, J Arribas, J Baselga Cancer research 61 (12), 4744-4749, 2001 10282001
4-) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerM Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ...Journal of the National Cancer Institute 99 (8), 628-638, 200710302007
5-) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five …J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, DG Kieback, ...Journal of clinical oncology 20 (21), 4292-4302, 200210172002
Google Scholar Visit Web Page
badge
University / Institution Rankings Fundacion Jimenez Diaz Rankings
AD Scientific Index ID 4990931
Web Of Science Researcher ID
H-Index , Verified Peer Reviews, Citing Articles
ORCID ID
Scopus Author ID
H-Index, Citations, Documents
Researchgate
Research Interest Score, h-index
 -
emoji_events
Awards & Achievements -
email
Email -
school
Academic Degree
web
Institutional Web Address fjd.es
verified_user
Office, Company or Private Business link -
books
Books - E-books -
note
Lecture Notes -
EDUCATION INFORMATION
Add your education information
JOB EXPERIENCES
Add your job experiences
Published Books
Add your published books
Editorship, Referee and Scientific Board
Add your editorship, referee and scientific board
Academic Grants and Awards
Add your academic grants and awards
Artistic Activities
Add your artistic activities
Certificate / Course / Trainings Attended
Add your certificate / course / trainings attended
Civil Society Memberships
Add your civil society memberships
Promotional Video
Add your promotional video